Considerations for the development of guidance on dose level selection for developmental and reproductive toxicity studies

被引:4
|
作者
Lewis, R. W. [1 ]
Andrus, A. K. [2 ]
Arroyo, J. [3 ]
Brescia, S. [4 ]
Botham, P. A. [5 ]
Corvaro, M. [6 ]
Daston, G. P. [7 ]
Hofmann, T. [8 ]
Rodriguez, C. [9 ]
Sewell, F. [10 ]
van Ravenzwaay, B. [11 ]
Wiench, K. [8 ]
Marty, S. [2 ]
机构
[1] Regulatory Sci Associates, Glasgow, Scotland
[2] Dow Chem Co USA, Midland, MI USA
[3] CEFIC, Brussels, Belgium
[4] Chem Regulat Div CRD, Hlth & Safety Execut, Bootle, England
[5] Syngenta, Jealotts Hill, England
[6] Corteva Agrisci Italia Srl, Rome, Italy
[7] Procter & Gamble, Cincinnati, OH USA
[8] BASF SE, Ludwigshafen, Germany
[9] Procter & Gamble, Strombeek Bever, Belgium
[10] Natl Ctr Replacement Refinement & Reduct Anim Res, London, England
[11] Environm Sci Consulting, Altrip, Germany
关键词
Dose selection; Reproductive and development toxicity; Maximum tolerated dose; Animal welfare; Regulatory guideline studies; 3Rs; EMBRYO-FETAL DEVELOPMENT; FEED RESTRICTION; TESTING STRATEGIES; DIGITAL DEFECTS; ETHYLENE-GLYCOL; RATS; TOXICOKINETICS; ORGANOGENESIS; ACID; MICE;
D O I
10.1016/j.yrtph.2024.105585
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
In 2022, the European Chemicals Agency issued advice on the selection of high dose levels for developmental and reproductive toxicity (DART) studies indicating that the highest dose tested should aim to induce clear evidence of reproductive toxicity without excessive toxicity and severe suffering in parental animals. In addition, a recent publication advocated that a 10% decrease in body weight gain should be replaced with a 10% decrease in bodyweight as a criterion for dose adequacy. Experts from the European Centre for Ecotoxicology and Toxicology of Chemicals evaluated these recent developments and their potential impact on study outcomes and interpretation and identified that the advice was not aligned with OECD test guidelines or with humane endpoints guidance. Furthermore, data analysis from DART studies indicated that a 10% decrease in maternal body weight during gestation equates to a 25% decrease in body weight gain, which differs from the consensus of experts at a 2010 ILSI/HESI workshop. Dose selection should be based on a biological approach that considers a range of other factors. Excessive dose levels that cause frank toxicity and overwhelm homeostasis should be avoided as they can give rise to effects that are not relevant to human health assessments.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Considerations for the development of guidance on dose level selection for developmental and reproductive toxicity studies
    Sewell, F.
    Marty, S.
    Botham, P.
    Lewis, D.
    TOXICOLOGY LETTERS, 2024, 399 : S294 - S294
  • [2] Practical consequences of ECHA's advice on dose level selection for reproductive toxicity studies
    Lohmann, B.
    Fuhlrott, J.
    Rohrig, R.
    Weber, M.
    TOXICOLOGY LETTERS, 2023, 384 : S127 - S128
  • [3] Recommendations on dose level selection for repeat dose toxicity studies
    Fiona Sewell
    Marco Corvaro
    Amanda Andrus
    Jonathan Burke
    George Daston
    Bryan Delaney
    Jeanne Domoradzki
    Carole Forlini
    Maia Louise Green
    Thomas Hofmann
    Sven Jäckel
    Moung Sook Lee
    Michael Temerowski
    Paul Whalley
    Richard Lewis
    Archives of Toxicology, 2022, 96 : 1921 - 1934
  • [4] Recommendations on dose level selection for repeat dose toxicity studies
    Sewell, Fiona
    Corvaro, Marco
    Andrus, Amanda
    Burke, Jonathan
    Daston, George
    Delaney, Bryan
    Domoradzki, Jeanne
    Forlini, Carole
    Green, Maia Louise
    Hofmann, Thomas
    Jackel, Sven
    Lee, Moung Sook
    Temerowski, Michael
    Whalley, Paul
    Lewis, Richard
    ARCHIVES OF TOXICOLOGY, 2022, 96 (07) : 1921 - 1934
  • [5] Review of dose setting for the extended one-generation reproductive toxicity studies (OECD TG 443): Considerations on ECHA's dose level selection recommendations
    Beekhuijzen, Manon
    Richmond, Emily
    Manton, Jason
    Coder, Pragati S.
    Goyak, Katy
    Ghaffari, Rashin
    Makris, Susan L.
    Van Cruchten, Steven
    Zorrilla, Leah
    Mitchell-Ryan, Shermaine
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2024, 151
  • [6] Developmental and Reproductive Toxicity Studies on Artemisone
    Schmuck, G.
    Klaus, A. -M.
    Kroetlinger, F.
    Langewische, F. W.
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2009, 86 (02) : 131 - 143
  • [7] Challenges of Species Selection for Development and Reproductive Toxicity Studies with a Dopamine Agonist
    Zhuang, Q.
    Rohde, M.
    Rasmussen, A. D.
    Jensen, K. G.
    Bernholm, K.
    Northeved, H.
    BIRTH DEFECTS RESEARCH, 2017, 109 (09): : 661 - 661
  • [8] Reproductive and developmental toxicity studies of manufactured nanomaterials
    Ema, Makoto
    Kobayashi, Norihiro
    Naya, Masato
    Hanai, Sosuke
    Nakanishi, Junko
    REPRODUCTIVE TOXICOLOGY, 2010, 30 (03) : 343 - 352
  • [9] Review of Reproductive and Developmental Toxicity Studies with Isopropanol
    Faber, Willem D.
    Pavkov, Kenneth L.
    Gingell, Ralph
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2008, 83 (05) : 459 - 476
  • [10] The rabbit as a model for reproductive and developmental toxicity studies
    Foote, RH
    Carney, EW
    REPRODUCTIVE TOXICOLOGY, 2000, 14 (06) : 477 - 493